

# Ly Tu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8299574/publications.pdf>

Version: 2024-02-01

74  
papers

4,623  
citations

126708

33  
h-index

102304

66  
g-index

79  
all docs

79  
docs citations

79  
times ranked

5167  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 780-789.	2.5	309
2	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	3.1	284
3	Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. <i>Respiratory Research</i> , 2009, 10, 6.	1.4	247
4	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016, 126, 3207-3218.	3.9	208
5	Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1041-1047.	2.5	196
6	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle–Like Cells in Pulmonary Hypertension. <i>Circulation</i> , 2014, 129, 1586-1597.	1.6	178
7	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. <i>Journal of Clinical Investigation</i> , 2009, 119, 512-523.	3.9	177
8	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. <i>European Respiratory Review</i> , 2013, 22, 543-551.	3.0	172
9	Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension. <i>Circulation Research</i> , 2006, 98, 1323-1330.	2.0	170
10	RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1151-1158.	2.5	165
11	Role for Interleukin-6 in COPD-Related Pulmonary Hypertension. <i>Chest</i> , 2009, 136, 678-687.	0.4	152
12	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 983-997.	2.5	144
13	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1332-1340.	1.6	141
14	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. <i>Chest</i> , 2015, 147, 529-537.	0.4	140
15	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 311-322.	1.4	125
16	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018, 128, 1956-1970.	3.9	125
17	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 895-904.	3.1	110
18	A Critical Role for p130Cas in the Progression of Pulmonary Hypertension in Humans and Rodents. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 666-676.	2.5	85

#	ARTICLE	IF	CITATIONS
19	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 910-924.	1.6	83
20	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2019, 124, 846-855.	2.0	81
21	Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22 $\alpha$ -targeted overexpression of the serotonin transporter. <i>FASEB Journal</i> , 2009, 23, 4135-4147.	0.2	80
22	Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1410-1420.	2.5	77
23	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. <i>Cardiovascular Research</i> , 2020, 116, 885-893.	1.8	70
24	Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 34, 1100-1110.	3.1	68
25	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1931-1940.	0.5	67
26	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 149, 1482-1493.	0.4	63
27	Leptin signalling system as a target for pulmonary arterial hypertension therapy. <i>European Respiratory Journal</i> , 2015, 45, 1066-1080.	3.1	62
28	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020, 116, 686-697.	1.8	54
29	Dasatinib increases endothelial permeability leading to pleural effusion. <i>European Respiratory Journal</i> , 2018, 51, 1701096.	3.1	50
30	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 766-782.	1.1	44
31	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 197.	1.6	40
32	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2014, 15, 65.	1.4	38
33	Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2019, 115, 432-439.	1.8	38
34	Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension. <i>JACC Basic To Translational Science</i> , 2017, 2, 22-35.	1.9	31
35	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 342-355.	2.5	30
36	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. <i>Nature Communications</i> , 2021, 12, 1720.	5.8	30

#	ARTICLE	IF	CITATIONS
37	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2000332.	3.1	28
38	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. <i>Cardiovascular Research</i> , 2022, 118, 1805-1820.	1.8	26
39	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 219-231.	0.4	26
40	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. <i>European Respiratory Journal</i> , 2019, 54, 1802400.	3.1	25
41	Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 1538-1546.	0.4	24
42	The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. <i>Cells</i> , 2020, 9, 1422.	1.8	23
43	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021, 117, 1391-1401.	1.8	23
44	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. <i>FASEB Journal</i> , 2019, 33, 3670-3679.	0.2	22
45	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4105.	1.8	21
46	Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 555.	1.3	21
47	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2725-2736.	2.9	20
48	Therapeutic potential of melatonin and melatonergic drugs on K18 <sup>hACE2</sup> mice infected with SARS-CoV-2. <i>Journal of Pineal Research</i> , 2022, 72, e12772.	3.4	20
49	The Thousand Faces of Leptin in the Lung. <i>Chest</i> , 2021, 159, 239-248.	0.4	18
50	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	2.9	17
51	Purinergic Dysfunction in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e017404.	1.6	16
52	Altered TGF $\beta$ 2/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention. <i>Cells</i> , 2021, 10, 84.	1.8	16
53	New targets for pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 377-385.	1.2	16
54	A genome-wide association analysis identifies PDE1A DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. <i>Oncotarget</i> , 2017, 8, 74917-74926.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Driving Role of Interleukin-2-Related Regulatory <sc>CD4</sc> + T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1387-1398.	2.9	13
56	Right lung ischemia induces contralateral pulmonary vasculopathy in an animal model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 967-973.	0.4	12
57	Angiomatoid fibrous histiocytoma of the pulmonary artery: a multidisciplinary discussion. <i>Histopathology</i> , 2014, 65, 278-282.	1.6	12
58	Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1900169.	3.1	12
59	Pulmonary Hemodynamic Responses to Inhaled NO in Chronic Heart Failure Depend on <i>PDE5</i> G(142)T Polymorphism. <i>Pulmonary Circulation</i> , 2011, 1, 377-382.	0.8	10
60	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 1248.	1.0	8
61	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013, , 409-436.	0.9	7
62	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 409-436.	0.9	6
63	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. <i>Arthritis Research and Therapy</i> , 2022, 24, 13.	1.6	6
64	Platelet-Derived Growth Factor Receptor Type 1 Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension. <i>Journal of the American Heart Association</i> , 2022, 11, e023021.	1.6	5
65	CD74-Dependent Interleukin-6 And Monocyte Chemoattractant Protein-1 Secretion By Pulmonary Endothelial Cells In Idiopathic Pulmonary Hypertension. , 2012, , .		3
66	Response by Guignabert et al to Letter Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". <i>Circulation Research</i> , 2019, 124, e82-e83.	2.0	2
67	Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. <i>Metabolites</i> , 2021, 11, 784.	1.3	2
68	Autoimmunity And Pulmonary Arterial Hypertension: The Role Of Leptin. , 2012, , .		1
69	P130Cas-Dependent Reversal Of Pulmonary Arterial Muscularization By Imatinib, Gefitinib And Dovitinib. , 2012, , .		1
70	The Hyperproliferative, Apoptosis-Resistant Phenotype Of Pulmonary Microvascular Endothelial Cells In Idiopathic Pulmonary Arterial Hypertension Is Partially Mediated By Autocrine Production Of FGF-2. , 2010, , .		0
71	Dichloroacetate Treatment Partially Regresses Established Pulmonary Hypertension In Mice With SM22-Targeted Over-expression Of The Serotonin Transporter. , 2010, , .		0
72	Consequences Of Alteration In TGF- $\beta$ /ALK1/Endoglin Signaling In The Pathogenesis Of Human And Rodent Pulmonary Arterial Hypertension. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
73	Pulmonary hypertension associated with neurofibromatosis type 2. <i>Pulmonary Circulation</i> , 2021, 11, 1-4.	0.8	0
74	Dasatinib increases endothelial permeability leading to pleural effusion. , 2017, , .		0